EXEL
NASDAQ · Biotechnology
Exelixis Inc
$48.16
+1.95 (+4.22%)
Financial Highlights (FY 2026)
Revenue
2.04B
Net Income
689.60M
Gross Margin
96.4%
Profit Margin
33.7%
Rev Growth
+12.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 96.4% | 96.4% | 35.4% | 35.4% |
| Operating Margin | 37.6% | 33.8% | -2.4% | -2.5% |
| Profit Margin | 33.7% | 32.0% | -2.9% | -3.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 2.04B | 1.81B | 2.68B | 3.17B |
| Gross Profit | 1.97B | 1.75B | 949.99M | 1.12B |
| Operating Income | 768.53M | 612.49M | -63,688,410 | -79,261,053 |
| Net Income | 689.60M | 549.58M | -77,688,294 | -100,603,820 |
| Gross Margin | 96.4% | 96.4% | 35.4% | 35.4% |
| Operating Margin | 37.6% | 33.8% | -2.4% | -2.5% |
| Profit Margin | 33.7% | 32.0% | -2.9% | -3.2% |
| Rev Growth | +12.9% | +12.9% | +9.9% | +16.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 749.88M | 797.27M |
| Total Equity | — | — | 4.56B | 4.48B |
| D/E Ratio | — | — | 0.16 | 0.18 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 794.02M | 667.95M | -84,355,918 | -102,546,027 |
| Free Cash Flow | — | — | -70,301,392 | -100,328,120 |